TNFSF10 and type 2 diabetes mellitus: Additionally, in a clinical setting, it has been shown that circulating soluble TRAIL levels are significantly reduced in patients in both T1DM and T2DM as well as in diabetes-related macro- and microvascular complications [21,22,23,24].